Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device

US8435550B2 · kind B2 · utility

Assignee

• Abbott Cardiovascular Systems, Inc. · US

Inventors

• Jin Q. Cheng · Tampa, US
• Stephen Dugan · San Francisco, US
• Gordon Stewart · San Francisco, US
• Gina Zhang · Calabasas, US
• Nancy Kirsten · Redwood City, US
• Paul Consigny · San Jose, US
• Christopher Feezor · Menlo Park, US
• Gene Park · Oakland, US
• Wouter E. Roorda · Newark, US
• Syed F. A. Hossainy · Fremont, US

Key dates

• Filing date: Aug 13, 2008
• Grant date: May 7, 2013
• Expiry date: Feb 14, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61L2300/45
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).